Keith Barrett, head of research at Ingenious Asset Management, asks whether outperformance in US healthcare stocks can continue or if it is time to take profits.
The US healthcare sector, ranging from health insurers to medical device makers to biotechnology companies, has risen by an annualised 21% since March 2009, notwithstanding the recent correction. It is easy to see why. An ageing population and the Affordable Care Act are boosting healthcare spending, benefitting the earnings of many healthcare companies. Premier's Robbins adds to US healthcare on strong jobs reports Meanwhile, companies in the pharmaceutical sector have also prospered as a result of improved research productivity. At a time of uncertain macro-economic conditions and...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
